FIRST-IN-HUMAN PHASE 1 STUDY OF TORL-1-23, A NOVEL CLAUDIN 6 (CLDN6) TARGETED ANTIBODY DRUG CONJUGATE (ADC) IN PATIENTS WITH OVARIAN CANCER

被引：0

作者：

Konecny, Gottfried ^{[1
]}

Hendrickson, Andrea Wahner ^{[2
]}

Winterhoff, Boris ^{[3
]}

Chander, Cinthiya ^{[1
]}

Bilic, Sanela ^{[4
]}

Davenport, Simon ^{[5
]}

Chung, Adrine ^{[6
]}

Miller, Lei-Lani ^{[6
]}

Press, Michael ^{[5
]}

Letrent, Stephen ^{[7
]}

Slamon, Dennis ^{[8
]}

机构：

[1] UCLA, Obstet & Gynecol, Los Angeles, CA USA

[2] Mayo Clin, 200 First St Sw, Rochester, MN USA

[3] Univ Minnesota, Div Gynecol Oncol, Minneapolis, MN USA

[4] Vanadro, Pharmacol, Urbandale, IA USA

[5] Univ Southern Calif, Dept Pathol, Los Angeles, CA USA

[6] Translat Res Oncol US, Clin Operat, Los Angeles, CA USA

[7] TORL Biotherapeut, Clin Dev, Culver City, CA USA

[8] Univ Calif Los Angeles, Dept Med, Los Angeles, CA USA

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2023年 / 33卷 / SUPPL_4期

关键词：

D O I：

10.1136/ijgc-2023-IGCS.102

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PR062

引用

页码：A67 / A67

页数：1

共 50 条

[21] Updated results from BNT211-01 (NCT04503278), an ongoing, first-in-human, phase I study evaluating safety and efficacy of CLDN6 CAR T cells and a CLDN6-encoding mRNA vaccine in patients with relapsed/refractory CLDN6+solid tumors
Haanen, J. B. A. G.
Mackensen, A.
Schultze-Florey, C.
Alsdorf, W.
Wagner-Drouet, E.
Heudobler, D.
Borchmann, P.
Busse, A.
Mielke, S.
Bins, S.
Ungerechts, G.
Bokemeyer, C.
Klobuch, S.
Kutsch, N.
Mueller, F.
Desuki, A.
Zhong, W.
Preussner, L.
Tuereci, Oe.
Sahin, U.
ANNALS OF ONCOLOGY, 2024, 35 : S489 - S490
[22] Phase 1 first-in-human study of KSI-301: a novel anti-VEGF antibody biopolymer conjugate with extended durability
Patel, Sunil S.
Naor, Joel
Qudrat, Almas
Do, Diana V.
Buetelspacher, Desiree
Liang, Hong
Perlroth, D. Victor
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
[23] First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors.
Demetri, George D.
Luke, Jason J.
Hollebecque, Antoine
Powderly, John D.
Spira, Alexander I.
Subbiah, Vivek
Lai, Dominic W.
Yue, Huibin
Kasichayanula, Sreeneeranj
Gulbranson, Scott
Purcell, James
Myzak, Melinda
Robinson, Randy
Villalobos, Victor Manuel
Tolcher, Anthony W.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[24] A first-in-human trial of intravesical enfortumab vedotin (EV), an antibody-drug conjugate (ADC), in patients with non-muscle invasive bladder cancer (NMIBC): Interim results of a phase 1 study (EV-104).
Kamat, Ashish M.
Lotan, Yair
Roupret, Morgan
Steinberg, Gary D.
Inman, Brant A.
Powles, Thomas
Redorta, J. Palou
Porten, Sima P.
Kulkarni, Girish S.
Uchio, Edward M.
Gorla, Seema Rao
Haas, Gabriel P.
Yu, Yao
Chia, Yen Lin
Birrenkott, Matthew
Kates, Max R.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[25] First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC), BAY 94-9343, in patients with advanced solid tumors.
Bendell, Johanna
Blumenschein, George
Zinner, Ralph
Hong, David
Jones, Suzanne
Infante, Jeffrey
Burris, Howard
Rajagopalan, Prabhu
Kornacker, Martin
Henderson, David
Kelly, Andrea
Hassan, Raffit
CANCER RESEARCH, 2013, 73 (08)
[26] First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)-targeting antibody-drug conjugate, in patients with small cell lung cancer
Morgensztern, Daniel
Ready, Neal E.
Johnson, Melissa Lynne
Dowlati, Afshin
Choudhury, Noura J.
Carbone, David Paul
Schaefer, Eric S.
Arnold, Susanne M.
Puri, Sonam
Piotrowska, Zofia
Hegde, Aparna Madhukeshwar
Chiang, Anne C.
Iams, Wade Thomas
Tolcher, Anthony W.
Nosaki, Kaname
Zha, Jiuhong
Li, Rui
Hingorani, Pooja
Jeng, Edwin E.
Furqan, Muhammad
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[27] A phase 1/2 study of LM-302, an anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate in patients with advanced gastric/gastroesophageal junction cancer.
Bai, Chunmei
Xue, Junli
Zheng, Yi
Sun, Meili
Ying, Jieer
Zhou, Fuxiang
Yu, Yiyi
Sun, Yuping
Xing, Ligang
Zhang, Yanqiao
Wen, Jinhua
Xiong, Jianping
Wu, Heshui
Yang, Xiuli
Wan, Lixin
Guo, Shiwei
Zhao, Rusen
Zhu, Zhizhen
Gong, Zhihua
Li, Jin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[28] First-in-human phase 1, dose-escalation and -expansion study of ABBV-399, an antibody-drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors
Angevin, E.
Kelly, K.
Heist, R.
Morgensztern, D.
Weekes, C.
Bauer, T. M.
Ramanathan, R. K.
Nemunaitis, J.
Fan, X.
Olyaie, O.
Parikh, A.
Reilly, E.
Afar, D.
Naumovski, L.
Strickler, J.
ANNALS OF ONCOLOGY, 2016, 27
[29] Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
Rudin, Charles M.
Pietanza, M. Catherine
Bauer, Todd M.
Ready, Neal
Morgensztern, Daniel
Glisson, Bonnie S.
Byers, Lauren A.
Johnson, Melissa L.
Burris, Howard A., III
Robert, Francisco
Han, Tae H.
Bheddah, Sheila
Theiss, Noah
Watson, Sky
Mathur, Deepan
Vennapusa, Bharathi
Zayed, Hany
Lally, Satwant
Strickland, Donald K.
Govindan, Ramaswamy
Dylla, Scott J.
Peng, Stanford L.
Spigel, David R.
LANCET ONCOLOGY, 2017, 18 (01): : 42 - 51
[30] A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer
Morgensztern, Daniel
Ready, Neal
Johnson, Melissa L.
Dowlati, Afshin
Choudhury, Noura
Carbone, David P.
Schaefer, Eric
Arnold, Susanne M.
Puri, Sonam
Piotrowska, Zofia
Hegde, Aparna
Chiang, Anne C.
Iams, Wade
Tolcher, Anthony
Nosaki, Kaname
Kozuki, Toshiyuki
Li, Tianhong
Santana-Davila, Rafael
Akamatsu, Hiroaki
Murakami, Haruyasu
Yokouchi, Hiroshi
Wang, Song
Zha, Jiuhong
Li, Rui
Robinson, Randy R.
Hingorani, Pooja
Jeng, Edwin E.
Furqan, Muhammad
CLINICAL CANCER RESEARCH, 2024, 30 (22) : 5042 - 5052

← 1 2 3 4 5 →